Today's Hours: 12:00pm - 8:00pm

Search

Did You Mean:

Search Results

  • Book
    volume editors, R. Pourmand.
    Contents:
    Acute neuropathies / Bromberg, M.B.
    Chronic neuropathies : chronic inflammatory demyelinating neuropathy and its variants / Ramchandren, S., Lewis, R.A.
    Nonsystemic vasculitic neuropathy : update on diagnosis, classification, pathogenesis, and treatment / Collins, M.P., Periquet-Collins, I.
    Dysimmune neuropathy / Kwan, J.Y.
    Autoimmune autonomic ganglionopathy / Winston, N., Vernino, S.
    Myasthenia gravis with anti-acetylcholine receptor antibodies / Meriggioli, M.N.
    Muscle-specific receptor tyrosine kinase antibody-positive and seronegative myasthenia gravis / Muppidi, S., Wolfe, G.I.
    Lambert-Eaton myasthenic syndrome / Pourmand, R.
    Idiopathic inflammatory myopathies / Dimachkie, M.M., Barohn, R.J.
    Stiff person syndrome / Duddy, M.E., Baker, M.R.
    Digital Access Karger 2009.
  • Article
    Wang C, Chan V, Yeung RT.
    Aust N Z J Med. 1979 Jun;9(3):225-32.
    Five men and three women with active acromegaly were treated with bromocriptine. After three months' therapy (30 mg/day) mean GH during the day decreased by 50% in six out of eight subjects. In the remaining two subjects (non-responders) GH was persistently over 100 micrograms/l. Mean GH during glucose tolerance test were not significantly decreased in three out of the eight subjects, of whom two were the nonresponders. The minimum dose of bromocriptine required to achieve maximum GH suppression ranged from 7.5 to 20 mg/day. In contrast, serum prolactin (PRL) throughout the day suppressed significantly in all subjects after 5 mg/day bromocriptine. Decreases in clinical symptoms, hand volume, urinary hydroxyproline and calcium excretion were seen in about half of the subjects. Three of the four subjects with diabetes mellitus showed improvement in glucose tolerance. Although minor side effects were uncommon, one patient died because of massive gastrointestinal haemorrhage from a duodenal ulcer.
    Digital Access Access Options